Bend Research Inc. (www.bendres.com), a leading independent drug-formulation development and manufacturing company, announced today that it is expanding its pharmaceutical manufacturing capabilities for hot-melt extrusion.
The company has purchased intermediate-scale equipment for hot-melt extrusion at its contract manufacturing facility to provide additional processing options for its clients.
The new equipment--an 18-mm extruder--provides capacity between existing 7.5-mm and 27-mm extruders. This enables manufacture at the appropriate scale for the development phase of the compound. The equipment reduces the amount of drug required for development work, resulting in savings to Bend Research clients and enables rapid, efficient advancement of compounds.
The three extruders enable seamless scale-up of a formulation from small-scale development work through large-scale manufacture of clinical supplies using cGMP regulations for human clinical trials.
"This added capability strengthens our established position as a leading drug-formulation outsource for pharmaceutical companies that need innovative delivery technologies," said Bend Research President and CEO Rod Ray. "In addition, the new equipment broadens the company's technology offerings for the delivery of low-solubility drugs."
Bend Research is a recognized international leader in the pharmaceutical industry for technologies that improve the solubility and bioavailability of hard-to-deliver pharmaceutical compounds. The company is well-known for its spray-dried dispersion (SDD) technologies, which have been used to advance hundreds of low-solubility compounds.